300 related articles for article (PubMed ID: 16000593)
1. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Golemovic M; Verstovsek S; Giles F; Cortes J; Manshouri T; Manley PW; Mestan J; Dugan M; Alland L; Griffin JD; Arlinghaus RB; Sun T; Kantarjian H; Beran M
Clin Cancer Res; 2005 Jul; 11(13):4941-7. PubMed ID: 16000593
[TBL] [Abstract][Full Text] [Related]
2. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Weisberg E; Manley PW; Breitenstein W; Brüggen J; Cowan-Jacob SW; Ray A; Huntly B; Fabbro D; Fendrich G; Hall-Meyers E; Kung AL; Mestan J; Daley GQ; Callahan L; Catley L; Cavazza C; Azam M; Neuberg D; Wright RD; Gilliland DG; Griffin JD
Cancer Cell; 2005 Feb; 7(2):129-41. PubMed ID: 15710326
[TBL] [Abstract][Full Text] [Related]
3. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
4. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
Verstovsek S; Golemovic M; Kantarjian H; Manshouri T; Estrov Z; Manley P; Sun T; Arlinghaus RB; Alland L; Dugan M; Cortes J; Giles F; Beran M
Cancer; 2005 Sep; 104(6):1230-6. PubMed ID: 16078266
[TBL] [Abstract][Full Text] [Related]
5. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
[TBL] [Abstract][Full Text] [Related]
6. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.
Fiskus W; Pranpat M; Bali P; Balasis M; Kumaraswamy S; Boyapalle S; Rocha K; Wu J; Giles F; Manley PW; Atadja P; Bhalla K
Blood; 2006 Jul; 108(2):645-52. PubMed ID: 16537804
[TBL] [Abstract][Full Text] [Related]
7. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.
Carter BZ; Mak DH; Shi Y; Schober WD; Wang RY; Konopleva M; Koller E; Dean NM; Andreeff M
Cell Cycle; 2006 Oct; 5(19):2223-9. PubMed ID: 16969080
[TBL] [Abstract][Full Text] [Related]
8. Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide.
Xia Y; Fang H; Zhang J; Du Y
Exp Biol Med (Maywood); 2013 Aug; 238(8):932-42. PubMed ID: 23883479
[TBL] [Abstract][Full Text] [Related]
9. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
13. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
14. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
15. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
16. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
Carter BZ; Mak DH; Schober WD; Cabreira-Hansen M; Beran M; McQueen T; Chen W; Andreeff M
Blood; 2006 Feb; 107(4):1555-63. PubMed ID: 16254145
[TBL] [Abstract][Full Text] [Related]
17. AMN107: tightening the grip of imatinib.
O'Hare T; Walters DK; Deininger MW; Druker BJ
Cancer Cell; 2005 Feb; 7(2):117-9. PubMed ID: 15710324
[TBL] [Abstract][Full Text] [Related]
18. Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
Orsolic N; Giles FJ; Gourdeau H; Golemovic M; Beran M; Cortes J; Freireich EJ; Kantarjian H; Verstovsek S
Br J Haematol; 2004 Mar; 124(6):727-38. PubMed ID: 15009060
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
O'Hare T; Walters DK; Stoffregen EP; Jia T; Manley PW; Mestan J; Cowan-Jacob SW; Lee FY; Heinrich MC; Deininger MW; Druker BJ
Cancer Res; 2005 Jun; 65(11):4500-5. PubMed ID: 15930265
[TBL] [Abstract][Full Text] [Related]
20. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]